Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–4 of 4 results
Advanced filters: Author: Noemie Leblay Clear advanced filters

  • Genomic and transcriptomic analysis of samples from patients with multiple myeloma, followed by in vitro validation, indicate mechanisms of antigen escape in response to GPRC5D T cell-engager talquetamab, including biallelic deletions, small nucleotide variants, insertion-deletions and chromatin silencing.

    • Holly Lee
    • Sungwoo Ahn
    • Nizar J. Bahlis
    ResearchOpen Access
    Nature Medicine
    P: 1-14

  • Tumor-intrinsic resistance mechanisms, including mutational events and immunoselection of mutant clones, were identified in 30 patients with multiple myeloma who experienced relapse after treatment with anti-BCMA CAR T cells and/or anti-BCMA bispecific T cell engagers (TCEs) or anti-GPRC5D TCE therapy.

    • Holly Lee
    • Sungwoo Ahn
    • Nizar J. Bahlis
    ResearchOpen Access
    Nature Medicine
    Volume: 29, P: 2295-2306

  • The molecular nature of large-cell neuroendocrine lung carcinomas (LCNEC) has remained unclear. Here, the authors show LCNECs represent a distinct transcriptional subgroup among lung cancers and comprise two molecular subgroups, type I (TP53 and STK11/KEAP1 alterations) and type II (TP53 and RB1 inactivation).

    • Julie George
    • Vonn Walter
    • Roman K. Thomas
    ResearchOpen Access
    Nature Communications
    Volume: 9, P: 1-13

  • Novel immunotherapeutic strategies based on targeting specific tumour-associated antigens with antibody–drug conjugates (ADCs), chimeric antigen receptor (CAR) T cells and bispecific T cell engagers (BTEs) are revolutionizing the treatment of multiple myeloma. In this Review, the authors describe the clinical experience to date with ADCs, CAR T cells and BTEs targeting B cell maturation antigen, G protein-coupled receptor family C group 5 member D and Fc receptor-like protein 5. In addition, they discuss the mechanisms of resistance to such therapies, and potential strategies by which resistance could be overcome to improve patient outcomes.

    • Paola Neri
    • Noémie Leblay
    • Kenneth C. Anderson
    Reviews
    Nature Reviews Clinical Oncology
    Volume: 21, P: 590-609